Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

  • Jai Perumal (Creator)
  • Roumen Deltchev Balabanov (Creator)
  • Ray Su (Creator)
  • Roger Chang (Creator)
  • Laura J. Balcer (Creator)
  • S. Galetta (Creator)
  • D. Campagnolo (Creator)
  • Robin Avila (Creator)
  • Lily Lee (Creator)
  • Danette Rutledge (Creator)
  • Robert J. Fox (Creator)
  • Steven Galetta (Creator)



Article full text The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2021.
Date made available2021
PublisherAdis Journals

Cite this